KMB
KIMBERLY-CLARK CORPORATIONPrice history
Chart: TradingView’s own feed · page prices: 1D EODSnapshot
SEC EDGAR · FY 2025-12-31Revenue & Earnings — fiscal year
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $19.4B | $17.0B | $17.1B | $16.8B | $16.4B |
| Gross Profit | $6.0B | $5.5B | $6.3B | $6.3B | $5.9B |
| Operating Income | $2.6B | $2.3B | $1.9B | $2.7B | $2.4B |
| Net Income | $1.8B | $1.9B | $1.8B | $2.5B | $2.0B |
| Diluted EPS | $5.35 | $5.72 | $5.21 | $7.55 | $6.07 |
| Operating Cash Flow | $2.7B | $2.7B | $3.5B | $3.2B | $2.8B |
| Free Cash Flow | — | — | — | — | — |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
FY25 cash-flow waterfall
KMB story timeline
Company updates and connected market context, with the dated price move attached.
Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say
Kimberly-Clark is preparing asset sales to secure EU approval for its proposed Kenvue deal, according to sources cited by Investing.com. The concessions could reduce regulatory friction but add execution risk and raise questions about the transaction’s eventual scope.
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark is seeking European Union approval for its proposed $40 billion acquisition of Kenvue, adding a regulatory hurdle to a major consumer-healthcare transaction. The setup now turns on the EU review and whether the deal can combine Kenvue’s higher gross margins with Kimberly-Clark’s larger revenue base without diluting execution.
Related Stocks
Click to explore
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.